

BAB VII

DAFTAR PUSTAKA

1. CDC - What Is Breast Cancer? [Internet]. [cited 2019 Nov 18]. Available from: https://www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm
2. The American Cancer Society. What is breast cancer? J Okla State Med Assoc [Internet]. 2012 [cited 2019 Sep 25];105(10):409–10. Available from: <https://www.cancer.org/cancer/breast-cancer/about/what-is-breast-cancer.html>
3. Organization WH. WHO | Breast cancer [Internet]. WHO. World Health Organization; 2018 [cited 2019 Sep 25]. Available from: <https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/>
4. Breast Statistics | American Cancer Society - Cancer Facts & Statistics [Internet]. [cited 2019 Sep 25]. Available from: https://cancerstatisticscenter.cancer.org/?_ga=2.261363085.1275630695.1569059435-1188519991.1567773407#!/cancer-site/Breast
5. Kementerian Kesehatan Republik Indonesia [Internet]. [cited 2019 Sep 25]. Available from: <http://www.depkes.go.id/article/view/19020100003/hari-kanker-sedunia-2019.html>
6. Post MWM. Definitions of quality of life: What has happened and how to move on. Top Spinal Cord Inj Rehabil. 2014 May 1;20(3):167–80.
7. Dimenäs ES, Dahlöf CG, Jern SC, Wiklund IK. Defining quality of life in medicine. Scand J Prim Health Care Suppl [Internet]. 1990 [cited 2019 Oct 21];1:7–10. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2100369>
8. WHO | WHOQOL: Measuring Quality of Life [Internet]. [cited 2019 Oct 21]. Available from: <https://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/>
9. HRQOL Concepts | CDC [Internet]. [cited 2019 Oct 21]. Available from: <https://www.cdc.gov/hrqol/concept.htm>

10. EORTC Quality of Life website | EORTC Quality of Life Group website : EORTC – Quality of Life [Internet]. [cited 2019 Oct 21]. Available from: <https://qol.eortc.org/>
11. EORTC. EORTC QLQ-C30 Scoring Manual The EORTC QLQ-C30 Introduction. EORTC QLQ-C30 Scoring Man [Internet]. 2001;30:1–67. Available from: <http://www.eortc.be/qol/files/scmanualqlq-c30.pdf>
12. Perwitasari DA, Atthobari J, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, et al. Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. *Jpn J Clin Oncol* [Internet]. 2011 Apr [cited 2019 Oct 21];41(4):519–29. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21266448>
13. Hwang SY, Chang SJ, Park BW. Does chemotherapy really affect the quality of life of women with breast cancer? *J Breast Cancer*. 2013 Jun;16(2):229–35.
14. Akin S, Can G, Durna Z, Aydiner A. *European Journal of Oncology Nursing* The quality of life and self-efficacy of Turkish breast cancer patients undergoing chemotherapy. *Eur J Oncol Nurs* [Internet]. 2008;12(5):449–56. Available from: <http://dx.doi.org/10.1016/j.ejon.2008.07.006>
15. Sharma N, Purkayastha A. Factors affecting quality of life in breast cancer patients: A descriptive and cross-sectional study with review of literature. *J Midlife Health* [Internet]. 2017 Apr 1 [cited 2020 Aug 23];8(2):75–83. Available from: </pmc/articles/PMC5496284/?report=abstract>
16. Rivard AB, Bhimji SS. *Anatomy, Thorax, Breast* [Internet]. StatPearls. 2018 [cited 2019 Nov 18]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30137859>
17. Zucca-Matthes G, Urban C, Vallejo A. *Anatomy of the nipple and breast ducts*. Vol. 5, *Gland Surgery*. AME Publishing Company; 2016. p. 32–6.
18. *Overview of the Breast - Breast Pathology* | Johns Hopkins Pathology [Internet]. [cited 2019 Sep 25]. Available from: <https://pathology.jhu.edu/breast/overview>

19. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Vol. 5, Genes and Diseases. Chongqing yi ke da xue, di 2 lin chuang xue yuan Bing du xing gan yan yan jiu suo; 2018. p. 77–106.
20. Kotsopoulos J. BRCA Mutations and Breast Cancer Prevention. *Cancers (Basel)*. 2018 Dec 19;10(12):524.
21. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. *Breast Cancer Res Treat*. 2017 Aug 1;165(1):193–200.
22. Nounou MI, Elamrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies supplementary issue: Targeted therapies in breast cancer treatment. *Breast Cancer Basic Clin Res*. 2015;9:17–34.
23. Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, Di Leo A, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas: Correlation with oncogene amplification in 160 cases. *Am J Clin Pathol*. 2000;113(5):675–82.
24. Hung MC, Lau YK. Basic science of HER-2/neu: A review. *Semin Oncol*. 1999;26(4 SUPPL. 12):51–9.
25. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: An overview. *J Adv Pharm Technol Res [Internet]*. 2010 Apr [cited 2019 Sep 25];1(2):109–26. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22247839>
26. Wang L. Early Diagnosis of Breast Cancer. *Sensors [Internet]*. 2017 Jul 5 [cited 2019 Oct 12];17(7):1572. Available from: <http://www.mdpi.com/1424-8220/17/7/1572>
27. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. *Cochrane Database Syst Rev [Internet]*. 2003 Apr 22 [cited 2019 Nov 19]; Available from:

<http://doi.wiley.com/10.1002/14651858.CD003373>

28. McCready T, Littlewood D, Jenkinson J. Breast self-examination and breast awareness: A literature review. Vol. 14, *Journal of Clinical Nursing*. 2005. p. 570–8.
29. Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS, Shih YCT, et al. Breast cancer screening for women at average risk: 2015 Guideline update from the American cancer society. Vol. 314, *JAMA - Journal of the American Medical Association*. American Medical Association; 2015. p. 1599–614.
30. Shah R, Rosso K, David Nathanson S. Pathogenesis, prevention, diagnosis and treatment of breast cancer. Vol. 5, *World Journal of Clinical Oncology*. Baishideng Publishing Group Co., Limited; 2014. p. 283–98.
31. Drukteinis JS, Mooney BP, Flowers CI, Gatenby RA. Beyond mammography: New frontiers in breast cancer screening. Vol. 126, *American Journal of Medicine*. 2013. p. 472–9.
32. Zeeshan M, Salam B, Khalid QSB, Alam S, Sayani R. Diagnostic Accuracy of Digital Mammography in the Detection of Breast Cancer. *Cureus*. 2018 Apr 8;
33. Miller RG. Breast cancer screening: Can we talk? *Journal of General Internal Medicine*. 2001;16(3):206–7.
34. Kerlikowske K, Hubbard RA, Miglioretti DL, Geller BM, Yankaskas BC, Lehman CD, et al. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: A cohort study. *Ann Intern Med*. 2011;155(8):493–502.
35. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. *Ann Intern Med* [Internet]. 2008 May 6 [cited 2019 Oct 30];148(9):671–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18458280>
36. Kriege M, Brekelmans CTM, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer

- screening in women with a familial or genetic predisposition. *N Engl J Med* [Internet]. 2004 Jul 29 [cited 2019 Oct 30];351(5):427–37. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15282350>
37. Van Goethem M, Tjalma W, Schelfout K, Verslegers I, Biltjes I, Parizel P. Magnetic resonance imaging in breast cancer. *Eur J Surg Oncol*. 2006;32(9):901–10.
 38. Sinha S, Sinha U. Recent advances in Breast MRI and MRS. *NMR Biomed*. 2009;22(1):3–16.
 39. O'Connor M, Rhodes D, Hruska C. Molecular breast imaging. *Expert Rev Anticancer Ther*. 2009;9(8):1073–80.
 40. Palmer ML, Tsangaris TN. Breast biopsy in women 30 years old or less. *Am J Surg* [Internet]. 1993 Jun [cited 2019 Nov 18];165(6):708–12. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8506971>
 41. Chaiwun B, Thorner P. Fine needle aspiration for evaluation of breast masses. Vol. 19, *Current Opinion in Obstetrics and Gynecology*. 2007. p. 48–55.
 42. Neal L, Sandhu NP, Hieken TJ, Glazebrook KN, Bride MB Mac, Dilaveri CA, et al. Diagnosis and management of benign, atypical, and indeterminate breast lesions detected on core needle biopsy. Vol. 89, *Mayo Clinic Proceedings*. Elsevier Ltd; 2014. p. 536–47.
 43. Kroese M, Zimmern RL, Pinder SE. HER2 status in breast cancer - An example of pharmacogenetic testing. *J R Soc Med*. 2007 Jul;100(7):326–9.
 44. Brooks M. Breast cancer screening and biomarkers. Vol. 472, *Methods in Molecular Biology*. 2009. p. 307–21.
 45. Bast J, Ravdin P, Hayes DF, Bates S, Fritsche H. J, Jessup JM, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. *J Clin Oncol*. 2001 Mar 15;19(6):1865–78.
 46. Koh J, Kim MJ. Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage. Vol. 20, *Korean Journal of Radiology*. Korean Radiological Society; 2019. p. 69–82.

47. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, et al. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: Time to modify the current American Joint Committee on Cancer staging system. *J Clin Oncol*. 2011 Dec 10;29(35):4654–61.
48. Edge SB, Byrd DR, Fritz AG, Fritz A, Greene FL, Trotti A, et al. *AJCC Cancer Staging Manual* [Internet]. [cited 2019 Nov 18]. Available from: <http://springer.com/978-0-387-88440-0>
49. Rapoport BL, Demetriou GS, Moodley SD, Benn CA. When and how do i use neoadjuvant chemotherapy for breast cancer? *Curr Treat Options Oncol*. 2014;15(1):86–98.
50. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. *Arch Pathol Lab Med* [Internet]. 2000 Jul [cited 2019 Nov 13];124(7):966–78. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10888772>
51. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol*. 2010;28(16):2784–95.
52. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Vol. 11, *Modern Pathology*. 1998. p. 155–68.
53. Hicks DG, Kulkarni S. HER2+ breast cancer: Review of biologic relevance and optimal use of diagnostic tools. Vol. 129, *American Journal of Clinical Pathology*. 2008. p. 263–73.
54. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Vol. 25, *Journal of Clinical*

- Oncology. 2007. p. 118–45.
55. Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Advances in novel drug delivery strategies for breast cancer therapy. Vol. 38, *Artificial Cells, Blood Substitutes, and Biotechnology*. 2010. p. 230–49.
 56. Matsen CB, Neumayer LA. Breast cancer: A review for the general surgeon. Vol. 148, *JAMA Surgery*. American Medical Association; 2013. p. 971–9.
 57. Akram M, Siddiqui SA. Breast cancer management: Past, present and evolving. In: *Indian Journal of Cancer*. 2012. p. 277–82.
 58. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. *Ann Oncol*. 2013;24(9):2206–23.
 59. Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2013;24(SUPPL.6).
 60. Puhalla S, Brufsky A, Davidson N. Adjuvant endocrine therapy for premenopausal women with breast cancer. *The Breast* [Internet]. 2009 Oct [cited 2019 Nov 18];18:S122–30. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0960977609702863>
 61. Christinat A, Lascio S Di, Pagani O. Hormonal therapies in young breast cancer patients: When, what and for how long? Vol. 5, *Journal of Thoracic Disease*. 2013.
 62. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. *Lancet Oncol*. 2011;12(7):631–41.
 63. Dowsett M, Stein RC, Coombes RC. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast

- cancer patients. *J Steroid Biochem Mol Biol* [Internet]. 1992 Sep [cited 2019 Nov 18];43(1–3):155–9. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/1388047>
64. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet*. 2013;381(9869):805–16.
 65. Shao N, Wang S, Yao C, Xu X, Zhang Y, Zhang Y, et al. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: A meta-analysis of phase III randomized control trials. *Breast*. 2012 Jun;21(3):389–93.
 66. Albain K, Anderson S, Arriagada R, Barlow W, Bergh J, Bliss J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. *Lancet*. 2012 Feb 4;379(9814):432–44.
 67. Valero V. Docetaxel and cyclophosphamide in patients with advanced solid tumors. *Oncology (Williston Park)* [Internet]. 1997 Jun [cited 2019 Nov 18];11(6 Suppl 6):21–3. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/9213323>
 68. Callahan R, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. *Curr Opin Obstet Gynecol* [Internet]. 2011 Feb [cited 2019 Nov 18];23(1):37–43. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/21500375>
 69. O’Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, et al. Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤ 2 cm: A meta-analysis of the randomized trastuzumab trials. *J Clin Oncol*. 2015 Aug 20;33(24):2600–8.
 70. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Vol. 31, *Drug Safety*. 2008. p. 459–67.

71. Turner N, Biganzoli L, Di Leo A. Continued value of adjuvant anthracyclines as treatment for early breast cancer. Vol. 16, *The Lancet Oncology*. Lancet Publishing Group; 2015. p. e362–9.
72. Johnson K, Blansett L, Kessler M, Kleinrock M, Lyle J, Biase S Di, et al. Innovation in cancer care and implications for health systems: Global oncology trend report. 2014;(May):61. Available from: <http://www.imshealth.com/portal/site/imshealth/menuitem.0be132395225d98ee566e5661ad8c22a/?vgnextoid=a64de5fda6370410VgnVCM10000076192ca2RCRD&vgnnextfmt=default>
73. Tsang RY, Finn RS. Beyond trastuzumab: Novel therapeutic strategies in HER2-positive metastatic breast cancer. Vol. 106, *British Journal of Cancer*. 2012. p. 6–13.
74. Swain SM, Im Y-H, Im S-A, Chan V, Miles D, Knott A, et al. Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA. *Oncologist*. 2014 Jul;19(7):693–701.
75. Papademetriou K, Ardavanis A, Kountourakis P. Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium. Vol. 2, *Journal of Thoracic Disease*. 2010. p. 160–70.
76. Definition of chemotherapy - NCI Dictionary of Cancer Terms - National Cancer Institute [Internet]. [cited 2019 Nov 17]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chemotherapy>
77. Definition of metastatic - NCI Dictionary of Cancer Terms - National Cancer Institute [Internet]. [cited 2019 Nov 19]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/metastatic>
78. Docetaxel - DrugBank [Internet]. [cited 2020 Aug 25]. Available from: <https://www.drugbank.ca/drugs/DB01248>

79. El Rassy E, Ghosn M, Farhat F, Bakouny Z, Assi T, Chahine G, et al. Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. *Breast Care* [Internet]. 2018 Apr 1 [cited 2020 Aug 25];13(2):121–5. Available from: <https://www.karger.com/Article/FullText/481339>
80. Angraini D, Semiarty R, Rasyid R, Khambri D. Faktor-Faktor Yang Mempengaruhi Kualitas Hidup Penderita Kanker Payudara Di Kota Padang. *J Endur*. 2018;3(3):562.

